• 20 Jan 2017

    Nemus Bioscience Announces Licensing Agreement with the University of Mississippi

    COSTA MESA, CA / ACCESSWIRE / January 11, 2017 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that the company had signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective use against bacteria, viruses, and fungi. The agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). 

    Brian Murphy, M.D., M.B.A., Nemus CEO and Chief Medical Officer, with expertise in infectious diseases commented, “Resistance to anti-infective therapies is a growing global health crisis that has significant impact for patients and their families, as well as society in the form of increased health-care management budgets to control the spread of these diseases. In addition to MRSA, we have seen a rise in resistant strains of fungi like Candida and Aspergillus, and among families of multiple viruses. While there has been a concerted effort to develop new therapeutic agents, some of these therapies have significant side-effects, cumbersome dosing, and are extremely expensive to manufacture. Cannabinoids offer a class of molecules notable for their safety profile and, through our manufacturing relationships, we believe these can be produced in a cost-effective manner.”

    “Cannabinoid receptors are located in just about every major organ in the body and are involved in cell-signaling related to the inflammatory response, healing, and even the development of scarring and fibrosis,” stated Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi. “In working with Nemus, we have developed a diverse platform of cannabinoid-related molecules that have therapeutic potential based on different routes of administration and activity against specific infectious organisms.”

    “This anti-infective platform will constitute the NB3000 series of Nemus molecules and formulations. In addition to developing this pipeline, the company is assessing the potential commercial value outside of the human anti-infective space to include veterinary and the anti-biofilm markets,” stated Dr. Murphy. “Given the bandwidth of potential uses, Nemus expects to actively pursue partnering opportunities for these candidate molecules with a goal that the monetization of these assets can be optimally leveraged.”


    This press release contains forward-looking statements, including statements about the potential benefits of the NB3000 series of molecules, as well as the timing of our near term, intermediate term, and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.


    The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS’ strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

    For more information, visit http://www.nemusbioscience.com.